Table 7.
35 Weeks Post-Commencement of MS/Mimotopic Peptide Therapy
| Epitope-Specific Serum IgE Signal: | |||
|
| |||
| ADARM | Pre-Rx | 249 | |
| ADARM | Post-Rx | -65 | |
| HSYQE | Pre-Rx | 278 | |
| HSYQE | Post-Rx | -64 | |
| KTGQF | Pre-Rx | 10 | |
| KTGQF | Post-Rx | -145 | |
|
| |||
| Epitope-Specific Serum (kappa + lambda) Signal: | |||
|
| |||
| ADARM | Pre-Rx | 1,766 | |
| ADARM | Post-Rx | -1,100 | |
| HSYQE | Pre-Rx | 2,145 | |
| HSYQE | Post-Rx | -761 | |
| KTGQF | Pre-Rx | 1,898 | |
| KTGQF | Post-Rx | -1,272 | |
|
| |||
| ADARM before Treatment: | ADARM after Treatment: | ||
|
| |||
| KL | 44,146,126 | KL | -27,502,151 |
| E/KL | 0.000006 | E/KL | -0.000002 |
| x 1 million | 6 | x 1 million | -2 |
|
| |||
| HSYQE before Treatment: | HSYQE after Treatment: | ||
|
| |||
| KL | 53,635,961 | KL | -5,363,596 |
| E/KL | 0.129790 | E/KL | -0.084132 |
| x 1 million | 129,790 | x 1 million | -84,132 |
|
| |||
| KTGQF before Treatment: | KTGQF after Treatment: | ||
|
| |||
| KL | 47,448,139 | KL | -1,272 |
| E/KL | 0.000000 | E/KL | -3,629,189 |
| x 1 million | 0.2 | x 1 million | -3,629,188,922,536 |
Thirty-five weeks following peptide-based MS therapy initiation. Test data end-results were similar to those illustrated in Table 4. Formula to Estimate MS Activity Factor (MSAF) = Net IgE/Net KL x 1,000,000. KL = specific (kappa + lambda) signal x 25,000 (Compensates for 1/25,000 serum dilution).